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Abstract 
Non-invasive epigenome editing is a promising strategy for engineering gene 
expression programs, yet potency, specificity, and persistence remain challenging. Here 
we show that effective epigenome editing is gated at single-base precision via ‘keyhole’ 
sites in endogenous regulatory DNA. Synthetic repressors targeting promoter keyholes 
can ablate gene expression in up to 99% of primary cells with single-gene specificity and 
can seamlessly repress multiple genes in combination. Transient exposure of primary T 
cells to keyhole repressors confers mitotically heritable silencing that persists to the 
limit of primary cultures in vitro and for at least 4 weeks in vivo, enabling manufacturing 
of cell products with enhanced therapeutic efficacy. DNA recognition and effector 
domains can be encoded as separate proteins that reassemble at keyhole sites and 
function with the same efficiency as single chain effectors, enabling gated control and 
rapid screening for novel functional domains that modulate endogenous gene 
expression patterns. Our results provide a powerful and exponentially flexible system 
for programming gene expression and therapeutic cell products. 
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Main 
Transcription factors (TFs) convert information encoded in regulatory DNA regions 
such as promoters and enhancers into gene expression and cell state outcomes. TFs are 
modular proteins that combine a DNA recognition domain with one or more domains 
that confer specific functions via interplay with other chromatin proteins1, 2. A key 
aspect of TF function derives from an ability to engage with double-stranded DNA and 
interact with native regulatory architectures assembled on the same template; notably, 
this property is not maintained in RNA-guided protein-DNA recognition, which 
involves extensive unwinding and disruption of the native DNA template3. The advent 
of synthetic DNA binding domains comprising linear combinations of zinc finger4, 5 or 
transcriptional activator-like (TAL)6, 7 DNA base recognition modules enables, in 
principle, the ability to program gene expression via selective targeting of covalently-
linked functional activities to regulatory regions.  
Systematic application of synthetic transcription factors for both basic and clinical 
research will require effectors that (i) can be targeted to precise genomic positions, (ii) 
are highly potent, and (iii) show single-gene-specific activity. The ability to program 
gene expression reliably without the potentially genotoxic sequelae of nucleases holds 
particular promise in therapeutic cell engineering 8-14. However, little is currently known 
concerning the precise mode(s) through which TF functional domains interact with 
native chromatin proteins to trigger changes in the expression of a specific gene.  
Despite decades of work on repressive domains such as the Kruppel-associated box 
(KRAB) 17, 22, it remains unclear what factors contribute to its activity in the context of a 
given promoter region.  In general, observed potencies have been highly variable, and 
complete repression has been elusive. Additionally, the impact of different types of 
functional domains on gene repression has been difficult to assess due to widely 
varying (or unreported) efficiencies of DNA targeting.  Achieving high specificity has 
been extremely challenging, with the result that potent single gene-specific repression 
in primary cells has not been achieved.  
While the potential for establishing mitotically heritable gene expression states appears 
to exist for a subset of genes harboring CpG islands within their promoter regions15-17, 
existing studies have not identified broadly-applicable tools or rules for conferring 
heritable gene expression programs on endogenous, dynamically regulated genes in 
primary cells. Prior attempts to engineer durable transcriptional repression have chiefly 
employed reporter constructs randomly integrated into transformed cell lines16-19 vs. 
targeting of endogenous genes.  As such, while the potential for mitotically heritable 
repression exists, its observation has been widely variable, and it has not been possible 
to disentangle contributions of binding, genomic position, and choice of functional 
domain. 
Here we report that the potency and specificity of epigenetic transcriptional repression 
are linked through promoter keyhole sites, the targeting of which triggers near-
complete repression with single-gene accuracy.  Potent repression, in turn, enables 
durable programming via reliable induction of mitotically heritable expression 
programs, offering new potential for engineered cell therapies.  
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Results 
Here we report the development of highly potent, specific, and mutliplexable synthetic 
repressors that can be deployed in primary human T cells to durably repress 
therapeutically relevant endogenous genes. Additionally, we dramatically broaden the 
application of synthetic repressors using a modular split system wherein DNA 
recognition and effector domains are encoded on separate polypeptides. 
For DNA recognition, we used the Xanthomonas TAL effector repeats 6, 7, which enable 
modular synthesis of DNA binding domains (DBDs) capable of targeting ~95% of the 
human genome sequence12, 20-22.  Synthetic TAL DBDs (T-DBDs) can be appended at 
either their C- or N-termini with effector domains conferring function in mammalian 
cells – for example the KRAB repressor domain15, 23. In both native and artificial TFs, 
KRAB domains recruit the KAP1 co-repressor and, in turn, endogenous enzymatic 
complexes that methylate histones and DNA and trigger focal heterochromatin 
formation23-28. 
Nucleotide-precise gating of epigenetic repression 
We focused initially on two major immune checkpoint genes: HAVCR2 (TIM3) and 
LAG3, both of which encode cell surface molecules.  Using a combination of DNase-seq 
and RNA-seq to map empirically the zone of transcription initiation 29 for each gene in 
primary T cells, we designed a series of densely spaced synthetic T-DBD-KRAB 
repressors targeting these regions (Fig. 1A,B).  To quantify efficacy, we electroporated 
repressor mRNA into primary T cells and measured the proportion of TIM3- or LAG3-
positive cells 48 hours post electroporation.  A priori, we expected that repressors 
targeting the same small region would be nearly equivalent in function.  Instead, for 
both genes we found that most synthetic repressors exhibited little to no function, while 
a small number exhibited highly effective gene repression.  Highly potent repressors 
were limited to specific promoter positions; four non-contiguous TIM3 repressors 
exhibited strong repression, with one (TM18) producing near-complete silencing, as did 
four LAG3 repressors with partially overlapping recognition sites distributed over 
~15bp (Fig. 1C-E).  Repression was accompanied by loss of H3K4me3 and gain of 
H3K9me3 as expected for KRAB-induced silencing (Fig. S1).  For both genes, targeting 
only a few nucleotides 5’ or 3’ did not evince significant repression.  Similar findings 
were evident when we repeated the above for another immune checkpoint gene, 
PDCD1(PD-1) (not shown). As such, the ability of synthetic DBD-KRABs to trigger 
repressor activity appears to be confined to highly specific ‘keyhole’ sites within gene 
promoters.  
We speculated that the keyhole phenomenon might result from tight positional (and 
hence rotational) constraints on the presentation of the KRAB domain. To test this, we 
devised a strategy for migrating the KRAB domain at 1bp intervals along both strands 
of a 115 bp region overlapping the keyhole site within the LAG3 promoter by means of 
synthetic repressors with incrementally extended DNA binding domains (Fig. 1F, S2A). 
This revealed discrete locations where migrating the KRAB domain even 1 bp 3’ or 5’ 
was sufficient to trigger strong repression from otherwise identical T-DBD-KRAB 
molecules (Fig. 1G, S2B,C). These results indicate that the epigenetic silencing cascade 
initiated by KRAB is precisely triggered at single nucleotide resolution by its linear (and 
hence rotational) positioning within promoter chromatin. 
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 Multiplex repression without loss of potency or specificity 
Delivery of potent TIM3 and LAG3 repressors (TM18 and LG09, respectively) both 
separately and simultaneously produced linearly additive results (Fig. 1E), indicating 
that synthetic repressors could be combined with no loss of potency. To quantify the 
specificity of repression – a key parameter for functional studies and potential clinical 
application – we measured global differential RNA transcription by total RNA-seq in 
primary T-cells 48h following electroporation of synthetic keyhole repressors of 
HAVCR2 (TIM3), LAG3, and PDCD1 (PD-1), applied individually (Fig. 2A-C, genome 
browser views, left) or simultaneously (Fig. 2D). Individual repressors ablated RNA 
expression of their target genes with near complete specificity (Fig. 2A-C, volcano plots, 
right). Of note, the LAG3 repressor resulted in down-regulation of the closely-
positioned gene PTMS located ~1kb upstream (Fig. 2B), consistent with a +/- ~2kb 
H3K9me3 ‘halo’ produced by KRAB-triggered silencing (Fig. S1). Notably, while LAG3 
was completely repressed, PTMS was only partially repressed (35% of control) (Fig. 2B).   
Simultaneous delivery of all three repressors produced additive effects with no loss of 
potency or specificity (Fig. 2D). We also observed both additivity and dose-dependence 
at the level of a single gene targeted by multiple synthetic repressors directed to 
different keyhole sites within the same promoter (Fig. S3). Synthetic repressors 
targeting keyhole sites thus exhibit both high potency and remarkable specificity and 
can be combined additively to produce T cell products with defined multi-gene 
expression patterns. 
Epigenetic persistence of gene repression programs 
We next studied the duration of the repressive effect as a function of synthetic repressor 
persistence. Repressor mRNA and protein are rapidly degraded, with protein returning 
to background levels by 48h post mRNA electroporation (Fig. S4). Following 
CD3/CD28 stimulation, primary T cells begin cycling with a doubling time of 
approximately 36 hrs.  As such, effects on gene expression persisting beyond 72 hours 
reflect mitotically heritable states.  In mock transfected cells, TIM3 expression peaks at 
~8 days post stimulation before beginning a gradual decline to steady state levels of 
~40% TIM3+ cells (Fig. 3A, open circles). By contrast, cells receiving the TM18 repressor 
show near complete repression of TIM3 up to day 5 post electroporation (day 7 post 
stimulation), and declining persistence of repression for another ~20 days, nearing the 
practical limit of T cell culture (Fig. 3A, solid black circles, red trace). The synthetic 
repressor targeting PD-1 provided nearly full repressive effect for two weeks in culture 
(Fig. 3B).  
To test for persistence of mitotically heritable repression in a longer duration, 
physiologically meaningful in vivo milieu, we applied a synthetic PD-1 repressor (PD02) 
to human T cells expressing an anti-CD19 chimeric antigen receptor (CAR) and infused 
these cells after 1 week in culture into female NOD/SCID gamma mice 30 that had been 
implanted five days prior with 5x105 human B-cell acute lymphoblastic leukemia (ALL) 
cells expressing CD19 (NALM-6 cells 31), at a dose expected to rapidly clear the 
leukemia cells.  In this physiologically stimulated milieu, serial peripheral blood 
measurements revealed persistence of PD-1 repression in infused T cells for 4 weeks 
post infusion, and thus 5 weeks post repressor transfection (Fig. 3C,D). As such, a 
transient pulse of a synthetic keyhole repressor is capable of establishing a mitotically-
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 heritable expression state at its target gene that persists within a substantial fraction of 
cells for an extended interval in a challenging in vivo setting.  
Therapeutic enhancement of CAR-T cells 
We next asked whether keyhole repressors of immune checkpoint genes, either alone or 
in combination, could potentiate CAR-T cell efficacy in vivo.  To test this, we engineered 
human anti-CD19 CAR-T cell products treated (separately) with keyhole repressors 
targeting PD-1, TIM3, and LAG3, and a multiplex dose of all three repressors 
simultaneously. The former achieved 98-99% repression of individual target genes, and 
the latter yielded a cell product with >97% of cells lacking PD-1, TIM-3, or LAG-3 (Fig. 
3E). We infused NSG mice (separately) with 2.5x105 CAR-T cells from each of these 
engineered cell products (plus non-engineered cell and CAR-T only controls) 6 days 
post NALM-6 tumor implantation (5 mice per arm).  All mice receiving CAR-T cells had 
no detectable tumor by 8 days post-infusion (14 days post tumor implantation) (Fig. 3E-
G), representing initial clearing of tumor by CAR-T.  We then re-challenged the mice 
with additional tumor cells at 21 days post-infusion (27 days post initial tumor 
implantation), a time when very few human CD3+ cells could be detected in peripheral 
blood (data not shown). Mice that received multiplex repressed (PD-1/LAG3/TIM3-
negative) CAR-T cells showed superior tumor control, with no relapses observed at 47 
days post initial tumor infusion (20 days post second tumor challenge) versus relapses 
in CAR-T-only or single checkpoint gene repressed cells. These results suggest that 
combining CARs with potent and durable epigenetic silencing of multiple immune 
checkpoint genes via keyhole repressors has the potential to increase the efficacy of 
therapeutic cell products.  
Split encoding of DNA binding and functional domains 
Having demonstrated high performance of synthetic transcription factor repressors for 
programming single or multiplex gene expression in vitro and in vivo, we next sought to 
develop an approach for generating complex synthetic factors capable of generating 
diverse cellular programs. Split encoding of DNA targeting and functional activities on 
separate molecules, as exemplified in RNA-guided systems such as Cas/CRISPR, offers 
substantial potential for flexibility and scale. We reasoned that if synthetic repressors 
could be decomposed into separately delivered T-DBDs and repressor domains that 
assembled in situ, it would be possible to screen large numbers of functional 
alternatives to KRAB by delivering them to the same keyhole site. It would also open 
new avenues for implementing complex combinatorial cell engineering programs. 
Orthogonal protein heterodimer pairs 32 offer an attractive system for ordered protein-
protein pairing.  However, the ability of such pairs to function in the complex 
environment of human cells is unknown.  We first tested whether T-DBD and KRAB 
domains could be split and efficiently assembled following electroporation as separate 
molecules. We designed modified synthetic repressors that incorporated one half of an 
orthogonal protein heterodimer pair (1 and 1’) (see Methods) after the C-terminal 
residue of the PD-1 synthetic repressor T-DBD. On a separately encoded molecule, we 
engineered its cognate half upstream of the N-terminal residue of KRAB.  Introduction 
of either the separately encoded T-DBD/heterodimer or heterodimer/KRAB proteins 
alone showed no effects on PD-1 gene expression (Fig. 4A, left). By contrast, parallel 
electroporation of separate mRNAs encoding each molecule produced potent 
repression nearly indistinguishable from that of the same T-DBD/KRAB synthetic 
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 repressor encoded by a single chain polypeptide (Fig. 4A, right and Fig. S5).  As such, 
an obligate heterodimer pair can enable the DNA binding and functional domains of 
synthetic transcription factors to be split and separately delivered in a flexible, and 
potentially highly scalable, manner. 
Alternative domains modulate persistence of repression 
To enrich further the functional repertoire of synthetic split TFs (SSTFs), we next 
explored the impacts on both potency and target expression kinetics of a wide range of 
candidate repressor domains extracted from native human TFs by delivering them to 
the keyhole site in the TIM3 promoter targeted by the DBD of TM18 (Fig. 4B,C).  We co-
delivered TM18-DBD-1 mRNA into primary human T-cells together with mRNA 
encoding each (separately) of the 77 candidate repressive domains shown in Fig. 4C 
fused to the 1’ heterodimer (Fig. 4D), and assayed TIM3 expression by flow cytometry 
over a 26 day interval. We identified numerous highly active repressive domains that 
differed chiefly in their temporal kinetics of repression (Fig. 4E,F).  Some SSTFs 
displayed an immediate sharp decline in repression at 5 days and complete loss by 2 
weeks (Fig. 4F). In contrast, different KRAB domain homologs from human zinc finger 
proteins exhibited a relatively slow kinetic profile of de-repression that extended to at 
least 26 days (Fig. 4E). The spatial presentation of functional domains, whether fused to 
the heterodimer at the C- or N-terminus, altered the repressive efficacy of at least one 
domain (MBD2), but not others (KRAB, CTBP1, and MECP2) (Fig. S6). Notably, we 
observed only modest repressive activity for DNA methyltransferase domains 16, 33 
when combined with the DNA binding domain of TM18, PD02, or LG09 (not shown).   
The above results thus show that SSTFs can be used to deliver different functional 
activities to the same keyhole site (or any other targeted site) at scale and indicate that 
different classes of repressive domains encoded within native TFs may confer different 
functions that are reflected chiefly in the kinetics of repression. 
Discussion 
In summary, we have shown that synthetic TFs combining TAL-DBDs with native 
repressor domains from human TFs are capable of producing near-complete gene 
silencing in primary T cells with extremely high specificity, in contrast to prior efforts 16, 
17, 34.  Repression is triggered at single nucleotide resolution, indicating a critical 
dependence on the spacing and rotational presentation of functional domains within 
promoters, which in turn relies on precise interactions with the native double-stranded 
DNA template. The remarkable potency, specificity, and additivity of keyhole 
repressors enable engineering of highly pure and potentially safer T cell products. The 
epigenetic durability of repression (>4 weeks in vivo) parallels the clinical effectiveness 
windows of recently described engineered cell therapies targeting lymphoid 
malignancies 35, opening the door for creation of epigenetically engineered therapeutic 
cell products with defined kinetics or natural ‘off switches’. As proof of concept, 
multiplex repression of the immune checkpoint genes PD-1, LAG3, and TIM3 in anti 
CD19 CAR-T cells resulted in enhanced efficacy compared with any individual 
repressor in a tumor re-challenge experiment, suggesting that this combination confers 
enhanced persistence and/or resistance to exhaustion.   
The ability to encode DNA targeting and functional activities on separate molecules 
with full retention of function that is conferred by obligate heterodimers offers 
unprecedented potential to create novel regulatory molecules that can be combined to 
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 program complex cell states. The availability of multiple orthogonal heterodimer pairs 
expands the effector engineering space exponentially, enabling in vivo assembly of 
polyfunctional molecules (Fig. S7A-D), and encoding of logic gates, among other 
applications. It should also be straightforward to incorporate split encoding of native 
double-strand DNA recognition and diverse functional activities into vector platforms 
(Fig. S7E) to enable highly complex large-scale genetic and epigenetic screening 
applications. 
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Fig. 1.  Potent silencing of gene expression in primary human T-cells triggered via 
nucleotide-precise placement of epigenetic repressor domains at keyhole sites. (a,b) 
Selection of repressors at the HAVCR2 (TIM3) and LAG3 promoters. Top: DNA binding 
domains (grey boxes) are shown to scale; tick marks indicate position of C-terminal KRAB 
domain. Red indicates ‘keyhole’ sites: DBD-KRABs with >90% repression.  Bottom: DNase-seq 
and RNA-seq normalized tag density. (c,d) Fraction of TIM3+ or LAG3+ cells (normalized to 
mock transfection) as quantified by flow cytometry 48 hours after electroporation of repressor 
mRNA into activated CD3+ human T-cells. (e) Left, activated T-cells were electroporated with 
no RNA, or mRNAs encoding TM18, LG09, or both TM18 and LG09.  Right, TIM3 and LAG3 
surface protein expression quantified by flow cytometry at 48 hours post-transfection (plots 
representative of three independent experiments). (Note: Residual LAG3+ peak in repressor-
treated cells results from bead autofluorescence of bead-cell complexes). (f) T-DBDs targeting 
seed sequences in the LAG3 promoter were sequentially extended by one repeat unit to produce 
groups of T-DBD-KRABs with different positioning of the C-terminal KRAB (see example 
group). (g) Fraction LAG3+ cells at 2 days post-transfection as measured by flow cytometry, 
normalized to no RNA controls. X-axis indicates the location of the KRAB domain relative to 
the LAG3 TSS. Groups 5 and 9 are highlighted to demonstrate loss/gain of repression activity 
when the KRAB domain was moved by one nucleotide. 
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Fig. 2. Multiplexing keyhole repressors does not affect individual potency or 
specificity (a) Left: RNA-seq tag density (scale bar in upper left) in PDCD1 locus following 
blank electroporation (top tracks, three independent replicates), and delivery of synthetic 
repressor PD02 targeting PDCD1 (bottom tracks, three independent replicates).  Right:  Volcano 
plot showing differential gene expression (RNA-seq q-value, vertical axis) following PD02 
repressor delivery. (b) Results for LAG3 synthetic repressor, as for (a). (c) Results for TIM3 
repressor, as for (a, b). Note that in addition to complete repression of LAG3, the PTMS gene 
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 located 1.2kb upstream is partly repressed. (d) Left, co-delivery of PD02, LG09, and TM18 
results in repression of target genes similar to individually delivered repressors. Right, volcano 
plot of differential gene expression (RNA-seq) q-values for co-delivered repressors consistent 
with linearly additive (and independent) contribution of each repressor. 
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 Fig. 3.  Repression is durable for a therapeutically-relevant window in engineered primary 
T cells.   (a) Kinetics of TIM3 repression by synthetic repressor TM18. Primary T cells were 
electroporated with either no RNA or TM18 at day 0, and TIM3 expression was determined by 
cell surface antibody staining and flow cytometry for 26 days. Cells with greater fluorescence 
intensity than unstained control were considered TIM3+. Percent TIM3+ cells is indicated by 
dark colored lines and left y-axis.  Fraction of cells with TIM3 repressed (%TIM3 negative cells 
in TM18-treated cells relative to no RNA control) is indicated by the right y-axis and red line. 
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 Bars indicate standard deviation of two electroporations in the same experiment. Repression was 
maintained through a time period equivalent to one population doubling. Population doubling 
time was calculated assuming a constant proliferation rate and cell counts at days 2 and 5. (b) 
Kinetics of PD-1 repression by synthetic repressor PD02 as in (a). PD1 expression was 
determined over the course of 15 days post-electroporation. (c,d) PD-1 repression by PD02 is 
maintained for 28 days in vivo in CAR-T cells. Anti-CD19 CAR-T cells were transfected with 
either no RNA or PD02 and transplanted into mice bearing NALM-6 human B cell leukemia 
xenograft tumors. Mouse blood was sampled periodically for 28 days following CAR-T cell 
infusion, and percent of human CD3+ cells expressing PD1 was determined by cell surface 
antibody staining and flow cytometry. ** P< 0.0066 for day 28 samples. (e,f,g) Multiplexed 
repression of PD-1, LAG3, and TIM3 confers a therapeutic benefit over single immune 
checkpoint repression in a tumor rechallenge model in vivo. NSG mice were implanted with 
CD19-expressing NALM-6 B-ALL tumors and treated with anti CD19 CAR-T cells 
programmed with synthetic repressors (e). Tumor burden was measured as total bioluminescence 
at the indicated timepoints (e). Total flux spider plots and mouse images show relapse in all 
treatment groups after rechallenge with tumor cells, with the exception of the CAR-T cells 
programmed with multiplexed repressors (f,g). 
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Fig. 4.  Split system using obligate heterodimers enables potent repression and large-scale 
analysis of functional domains.  (a) Activated primary human T cells were electroporated with 
author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.02.19.956730doi: bioRxiv preprint 
 no RNA or components of synthetic repressor PD02 targeting PD-1. Cells were electroporated 
with: no RNA, DNA binding domain fused to heterodimer 1 (PD02-1) alone, KRAB domain 
fused to heterodimer 1’ (1’-KRAB) alone, both DNA binding domain and KRAB fused to 
respective heterodimers (equimolar amounts of separate molecules, combined in same 
electroporation), or DNA binding domain fused to KRAB (PD02-KRAB). Electroporated 
components indicated as cartoons above respective FACS plots. PD-1 expression was 
determined by cell surface antibody staining and flow cytometry 48 hours after electroporation.  
(b) Conceptual diagram of epigenetic domain screening utilizing the protein heterodimer system: 
1:1’. Different epigenetic effector domains fused to 1’ can be co-delivered and screened for 
activity at scale with a given keyhole-targeted DNA binding domain fused to the heterodimer 
partner, 1’.  (c) Genes from which candidate repressor domains were selected for screening.  (d) 
The DNA binding domain of the TIM3 repressor TM18 was selected to screen additional 
functional domains. TM18-DBD was fused to heterodimer 1, and a library of domains was fused 
to heterodimer 1’. (e,f) Both constructs were transiently expressed in primary human T cells by 
RNA electroporation, and fraction of cells with TIM3 repressed (%TIM3 negative cells in 
TM18-treated cells relative to no RNA control) was evaluated periodically for 26 days by cell 
surface antibody staining and flow cytometry. Cells with greater fluorescence intensity than 
unstained control were considered TIM3+. (e) Domains containing KRAB showed more durable 
repression, or relatively slow kinetics of decay, for several different KRAB domains show on the 
left with conceptual diagram (right). (f) Domains from methyl-DNA binding proteins (see 
supplemental table S2) showed less durable repression, or relatively fast kinetics of decay (left), 
with conceptual diagram (right). 
author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprint (which was not peer-reviewed) is the. https://doi.org/10.1101/2020.02.19.956730doi: bioRxiv preprint 
